Rosetta Genomics Stock Fundamentals
Rosetta Genomics fundamentals help investors to digest information that contributes to Rosetta Genomics' financial success or failures. It also enables traders to predict the movement of Rosetta Stock. The fundamental analysis module provides a way to measure Rosetta Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rosetta Genomics stock.
Rosetta |
Rosetta Genomics Company Return On Equity Analysis
Rosetta Genomics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Rosetta Genomics Return On Equity | -137.95 |
Most of Rosetta Genomics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rosetta Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Rosetta Genomics has a Return On Equity of -137.95. This is much higher than that of the sector and 108.6% higher than that of the Return On Equity industry. The return on equity for all United States stocks is notably higher than that of the company.
Rosetta Genomics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rosetta Genomics's current stock value. Our valuation model uses many indicators to compare Rosetta Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rosetta Genomics competition to find correlations between indicators driving Rosetta Genomics's intrinsic value. More Info.Rosetta Genomics is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rosetta Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rosetta Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Rosetta Genomics' earnings, one of the primary drivers of an investment's value.Rosetta Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rosetta Genomics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rosetta Genomics could also be used in its relative valuation, which is a method of valuing Rosetta Genomics by comparing valuation metrics of similar companies.Rosetta Genomics is currently under evaluation in return on equity category among related companies.
Rosetta Fundamentals
Return On Equity | -137.95 | |||
Return On Asset | -60.19 | |||
Operating Margin | (370.55) % | |||
Current Valuation | 2.09 M | |||
Shares Outstanding | 5.93 M | |||
Shares Owned By Insiders | 0.20 % | |||
Shares Owned By Institutions | 14.42 % | |||
Number Of Shares Shorted | 310.26 K | |||
Price To Earning | (0.09) X | |||
Price To Book | 1.01 X | |||
Price To Sales | 0.72 X | |||
Revenue | 2.86 M | |||
Gross Profit | 498 K | |||
EBITDA | (10.35 M) | |||
Net Income | (9.48 M) | |||
Cash And Equivalents | 1.32 M | |||
Cash Per Share | 0.51 X | |||
Total Debt | 2.45 M | |||
Debt To Equity | 222.80 % | |||
Current Ratio | 2.09 X | |||
Book Value Per Share | 0.43 X | |||
Cash Flow From Operations | (11.68 M) | |||
Short Ratio | 1.54 X | |||
Earnings Per Share | (6.41) X | |||
Price To Earnings To Growth | (0.01) X | |||
Number Of Employees | 86 | |||
Beta | 0.64 | |||
Market Capitalization | 2.07 M | |||
Total Asset | 22.42 M | |||
Retained Earnings | (140.27 M) | |||
Working Capital | 16.57 M | |||
Current Asset | 19.37 M | |||
Current Liabilities | 2.8 M | |||
Z Score | -8.4 |
Currently Active Assets on Macroaxis
LTC | Litecoin | |
STETH | Staked Ether | |
LINK | Chainlink | |
XLM | Stellar | |
CRO | Cronos |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Rosetta Stock
If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |